Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$74.45 USD
+0.67 (0.91%)
Updated Aug 19, 2024 03:59 PM ET
After-Market: $74.43 -0.02 (-0.03%) 7:18 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$74.45 USD
+0.67 (0.91%)
Updated Aug 19, 2024 03:59 PM ET
After-Market: $74.43 -0.02 (-0.03%) 7:18 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals
Intercept (ICPT) Gains on Earnings and Revenue Beat in Q3
by Zacks Equity Research
Intercept's (ICPT) revenues beat estimates, owing to strong Ocaliva sales in the third quarter of 2018.
Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal
by Zacks Equity Research
Impressive third-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.
Aduro (ADRO) Q3 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
Aduro's loss (ADRO) betters estimates in Q3. However, lower license and collaboration fees induce a dip in year-over-year revenues.
Can the Strong Economy Save the Stock Market?
by John Blank
The U.S. economy is the MOST important fundamental.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $70.90, marking a +1.66% move from the previous day.
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2
by Zacks Equity Research
Dr. Reddy's (RDY) surpasses earnings and revenue estimates on strength across segments in the second quarter of fiscal 2019.
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers (Revised)
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers
Top Analyst Reports for Johnson & Johnson, UnitedHealth, AT&T & Intel
by Mark Vickery
Today's Research Daily features new research reports on 17 major stocks, including Johnson & Johnson (JNJ), UnitedHealth (UNH), AT&T (T) and Intel (INTC).
Gilead (GILD) Beats on Q3 Earnings & Sales, Updates View
by Zacks Equity Research
Gilead's (GILD) third-quarter results beat estimates. However, persistent decline in HCV sales is disappointing.
New Batch of Q3 Earnings: AMZN, GOOGL, INTC & More
by Mark Vickery
Big afternoon of new quarterly earnings releases after the bell today, with some of the world's largest technology firms hitting the tape.
Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 10.84% and 2.95%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Vertex (VRTX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vertex' (VRTX) Q3 gains on earnings and revenue beat with demand for its CF products rising high.
Bristol-Myers (BMY) Beats on Q3 Earnings, Raises EPS View
by Zacks Equity Research
Bristol-Myers (BMY) beats earnings estimates in the third quarter but misses sales expectation by a slight margin. Eliquis and Opdivo continue to record solid sales.
Sarepta (SRPT) Q3 Earnings & Sales Miss, Exondys 51 Sales Up
by Zacks Equity Research
Sarepta (SRPT) misses estimates on both counts in third-quarter 2018. However, Exondys 51 performs well on strong demand.
Healthcare ETFs to Buy Ahead of Q3 Earnings
by Sweta Killa
The positive estimate revisions suggest continued outperformance for the healthcare ETFs.
Alexion's (ALXN) Earnings Beat Estimates in Q3, Guidance Up
by Zacks Equity Research
Alexion (ALXN) beats earnings estimates and marginally misses sales estimates in the third quarter of 2018. The company also inks a deal to acquire Syntimmune for $1.2 billion.
Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release their third-quarter results on Oct 25. Let???s take a look at how these companies are poised ahead of their earnings release.
Alkermes (ALKS) Exceeds Q3 Earnings Estimates, Raises Outlook
by Zacks Equity Research
Alkermes (ALKS) surpasses earnings and sales expectations in the third quarter of 2018 and raises its financial guidance for 2018.
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers
Will Gilead (GILD) HIV Sales Offset HCV Sales Decline in Q3?
by Zacks Equity Research
Gilead Sciences (GILD) is scheduled to report third-quarter results on Oct 25. We expect investors to focus on the strong HIV franchise and other pipeline updates.
Earnings Keep Pouring In: Global Week Ahead
by John Blank
So far, almost 90% of the firms have beaten analysts' earnings expectations. About 70% have beaten revenue expectations. This week, 156 S&P 500 firms release earnings.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $74.17, marking a -1.92% move from the previous day.
Gilead Sciences (GILD) Q3 Earnings Preview: What to Expect
by Zacks Equity Research
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $73.59, marking a +1.5% move from the previous day.